| Studie Sinopharm-Impfstoff mit deaktivierten Viren |  |
[https://www.wam.ae/en/details/1395302893589]
Bringt ebenfalls sehr gute Ergebnisse (Phase III Zwischenergebnis).
"MOHAP, in collaboration with Department of Health Abu Dhabi, DOH, has reviewed Sinopharm CNBG’s interim analysis of the phase III trials, which shows Beijing Institute of Biological Product’s inactivated vaccine to have 86 percent efficacy against COVID-19 infection. The analysis also shows the vaccine to have 99 percent seroconversion rate of neutralising antibody and 100 percent effectiveness in preventing moderate and severe cases of the disease. Furthermore, the analysis shows no serious safety concerns."
Unwahrscheinlich, dass wir diesen Impfstoff in der EU sehen werden aber vielleicht für ähnliche interessant.